Could have systemic side effects
MT-2 10mg Research Peptide Supplied in Thailand MT-2 (Melanotan II) is a synthetic peptide supplied as a high-purity lyophilised powder (HPLC/MS verified)
Alexiev BA, Chou PM, Jennings LJ
A periodic dermatological examination is generally recommended for patients with dysplastic nevi or AMS, ranging from an examination every 3-12 months, depending on a patient's position within the risk spectrum described above.3 Thus, some authors propose that patients of Rigel's group 0 be examined annually, while those with higher risk (Rigel I, II or III) should be evaluated by a dermatologist every 3 to 6 months.3 According to Tucker et al.32, the risk of melanoma for patients with AMS in families predisposed to melanoma begins to increase at around 10 years of age and so it is recommended that monitoring begin at puberty.3 Physical examination of the entire integument is essential because most melanomas occur on covered areas and previous studies have demonstrated that the detection of melanoma was 6 times more frequent in patients who undressed completely.3,48 As mentioned above, dermoscopy increases the diagnostic accuracy of melanocytic neoplasias, and its implementation is recommended during dermatologic consultation.48,49,50,51 However, even with the aid of a dermatoscope, identification of new lesions and significant changes in nevi in individuals with multiple pigmented lesions and AMS can be challenging, making total body mapping and digital dermoscopy of great benefit to the diagnostic process.43,44 In the protocol followed by the Dermoscopy Clinic of the Skin Oncology Department of Hospital AC Camargo, risk patients are reevaluated 3 months after the first visit, with a third evaluation 6 months after the last one, followed by annual tracking
